NIH Research Festival 2012 Program - Research Festival - National ...
NIH Research Festival 2012 Program - Research Festival - National ...
NIH Research Festival 2012 Program - Research Festival - National ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Concurrent Symposia Session I<br />
Natcher Conference Center<br />
Balcony C<br />
Tuesday, October 9, <strong>2012</strong><br />
3:00 p.m.–5:00 p.m.<br />
Development of neuroimaging based biomarkers<br />
Co-Chairs: Barry Horwitz, NIDCD; and Richard Coppola, NIMH<br />
The three fundamental steps necessary for the clinical management of a brain disorder<br />
are (1) detection and diagnosis, (2) treatment, and (3) assessment of treatment response.<br />
Biomarkers are important for the first and third of these, and may provide targets for<br />
treatment. Importantly, a biomarker refers to the underlying disease state, not to the<br />
symptoms of a disorder per se. In this symposium, the focus will be on attempts to<br />
develop neuroimaging biomarkers for detection, diagnosis and treatment assessment.<br />
In particular, neuroimaging can potentially provide both structural and functional brain<br />
biomarkers. Recently, advances in neuroimaging have shifted attention from examining<br />
individual brain regions to focusing on brain networks, and neuroimaging biomarker<br />
development has followed this shift. Speakers will discuss various uses of neuroimaging<br />
biomarkers, as well as some specific applications to neurologic and psychiatric disorders.<br />
Barry Horwitz, NIDCD<br />
What can brain based biomarkers be used for?<br />
James Blair, NIMH<br />
fMRI biomarkers for differentiating forms of Conduct Disorder<br />
Brian Cornwell, NIMH<br />
Markers of cortical plasticity in antidepressant action<br />
Silvina Horovitz, NINDS<br />
State-dependent and disease related variations in functional networks<br />
Richard Coppola, NIMH<br />
Tracking brain network changes during training and cognitive remediation<br />
Samuel Hasson, NINDS<br />
Next-generation therapeutic avenues for neurodegenerative disease: Targeting Pink1 and<br />
Parkin to modulate mitochondrial quality control<br />
FARE Award Winner<br />
21